Web-Base App To Improve Aromatase Inhibitor Adherence

Completed · Not applicable

Conditions studied: Breast Neoplasm Female

In brief

The purpose of this study will be to test the use of a web-based mobile application (app) initiated at the time of the initial prescription to an aromatase inhibitor to improve communication and management of treatment-related adverse symptoms among patients with hormone-receptor positive breast cancer.

Key facts

Study ID

NCT02957526

Run by

University of Tennessee

People needed

44

Starts

2015-12-01

Expected to finish

2016-07-01

Last updated by the study team

2018-07-19

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Adult female patients (age≥18)
• Diagnosed with early stage (I-III) HR+ breast cancer
• New prescription for an aromatase inhibitor
• Have a mobile device with a data plan or a home computer with Internet
• Have a valid email address
• Willing to complete brief weekly symptom reports on the app

You may not qualify if…

• Unable to communicate in English
• Patients with prior use of adjuvant endocrine therapy will also be excluded
• Patients concurrently undergoing surgery, chemotherapy or radiation will also be excluded
• Current diagnosis of rheumatoid arthritis
• Chronic daily narcotic usage

Where it is running

• West Cancer Center, MIDTOWN, 1588 Union Ave. — Memphis, Tennessee, United States
• West Cancer Center, EAST MEMPHIS, 7945 Wolf River Blvd — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.